PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint

PDS Biotechnology Corp

Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.
R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.
VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.
PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.
New US and Japan patents granted for PDS0101, extending market protection into 2040s.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PDS Biotechnology Corp reported the quarter ended March 31, 2026 results: net income net loss of approximately $7.3 million, EPS $0.13 per basic and diluted share.

Period: the quarter ended March 31, 2026
Net income: net loss of approximately $7.3 million
EPS: $0.13 per basic and diluted share
Result: reported results

Exact text from the filing

Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PDS Biotechnology Corp filing history →

Source: SEC EDGAR

accession 0001140361-26-020934

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.